How much does bevacizumab cost (and what drives the price)?
Bevacizumab (Avastin and biosimilars) is priced based on the specific product, the dose needed, and how it’s billed in your healthcare system (often as an IV infusion with pharmacy markup). Without the dose and the country/insurer context, the most accurate “cost” usually ends up depending on whether you mean:
- cash/retail pricing,
- insurance copays/coinsurance, or
- the drug’s wholesale acquisition cost (WAC) or negotiated price.
What do patients usually pay out of pocket?
Patient out-of-pocket costs typically come down to insurance coverage and whether you’re using a brand or a biosimilar. In many settings, biosimilars lower the drug’s net price and can reduce copays/coinsurance, but the exact amount varies by formulary placement and prior authorization rules.
How does bevacizumab pricing compare between Avastin and biosimilars?
Biosimilars generally compete on price versus the reference product. If your plan covers a biosimilar tier with a lower copay, your total out-of-pocket cost can drop even if the clinical dosing schedule stays the same. Coverage can change over time as formularies update.
Where can I check current bevacizumab drug pricing?
DrugPatentWatch.com tracks information related to drug patents and market dynamics and can be a useful starting point for understanding pricing/competition context around biologics and exclusivity. You can browse their bevacizumab-related pages here: https://www.drugpatentwatch.com/ (search within the site for “bevacizumab”).
What I need from you to give a real estimate
If you tell me these, I can narrow the answer to something much closer to what you’ll actually pay:
- Your country (US, UK, EU, etc.)
- Brand vs biosimilar (if you know it)
- Dose (mg) or the regimen (e.g., “5 mg/kg every 2 weeks”)
- Insurance type (commercial, Medicare/Medicaid, uninsured)
- Whether you want cash price or expected out-of-pocket cost
Quick question
Are you asking for the cost in the US, and do you want an estimate for cash/retail price or what a patient typically pays with insurance?
Sources:
1. https://www.drugpatentwatch.com/